Pioneering the development of novel
immuno-oncology and immune therapies
Our Team
The HaemaLogiX team is researching immune-based treatments that target unique antigens on malignant cells to improve the quality of life of patients suffering from blood cancers.
Our Pipeline
Our research platform involves multiple approaches in treating Multiple Myeloma – a blood cancer, and AL Amyloidosis – a life-threatening abnormal protein build-up in tissues and organs.
Our Innovation
Following the discovery of two unique antigens on malignant Bone Marrow Cells, we are developing Monoclonal Antibodies, CAR T cell Therapies and Bispecific Antibodies that specifically target those malignant cells.
